DALLAS, Oct. 25, 2021 /PRNewswire/
-- Lantern Pharma (NASDAQ: LTRN), a clinical
stage biopharmaceutical company using its proprietary RADR®
artificial intelligence ("A.I.") platform to transform the cost,
pace, and timeline of oncology drug discovery and development,
announced today that it will host a conference call on Monday, November 1, 2021 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
Management intends to discuss the financial and operating
results for the third quarter ended September 30, 2021 and provide guidance on
upcoming milestones. The call will be led by Panna Sharma, President and Chief Executive
Officer of Lantern Pharma. He will be joined on the call by other
members of the management team.
To register for the live webcast, please sign up
here: https://zoom.us/webinar/register/6716351795676/WN_s_xTDUXeRB6Lq55SItCPdQ
To access the conference by phone:
One-tap dial-in: +19292056099,,99145071949#
A replay of the conference call will be available on the
investor relations section of the Company's website:
ir.lanternpharma.com.
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. platform and
machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across eight disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and
Twitter @lanternpharma.
Lantern Pharma Investor Relations
Contact:
David Waldman,
Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying
drug candidates and patient populations that are likely to respond
to a drug candidate; our strategic plans to advance the development
of our drug candidates and antibody drug conjugate (ADC)
development program; estimates regarding the development timing for
our drug candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the
drug development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that none of our product candidates has
received FDA marketing approval, and we may not be able to
successfully initiate, conduct, or conclude clinical testing for or
obtain marketing approval for our product candidates, (iii) the
risk that no drug product based on our proprietary RADR A.I.
platform has received FDA marketing approval or otherwise been
incorporated into a commercial product, and (iv) those other
factors set forth in the Risk Factors section in our Annual Report
on Form 10-K for the year ended December 31, 2020, filed with
the Securities and Exchange Commission on March 10, 2021. You
may access our Annual Report on Form 10-K for the year
ended December 31, 2020 under the investor SEC filings
tab of our website at www.lanternpharma.com or on the
SEC's website at www.sec.gov. Given these risks and
uncertainties, we can give no assurances that our forward-looking
statements will prove to be accurate, or that any other results or
events projected or contemplated by our forward-looking statements
will in fact occur, and we caution investors not to place undue
reliance on these statements. All forward-looking statements in
this press release represent our judgment as of the date hereof,
and, except as otherwise required by law, we disclaim any
obligation to update any forward-looking statements to conform the
statement to actual results or changes in our expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-host-third-quarter-2021-operating--financial-results-conference-call-on-monday-november-1-2021-at-430-pm-et-301407949.html
SOURCE Lantern Pharma